$CABA News

Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

Cabaletta Bio Presents New Clinical Data Supporting Rese-Cel As Potential Treatment For Multiple Autoimmune Diseases, At EULAR 2026 Congress

Cabaletta Bio (CABA) Upgraded to Buy: Here's Why

Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Raises Price Target to $4

Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting

Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune

Cabaletta Bio Q1 EPS $(0.39), Inline

Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $30 Price Target

Cabaletta Prices Share Sale Of 51.73M Shares at $2.90 to Fund Autoimmune Therapy Development

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Cabaletta Bio Announces Commercial Agreement With Cellares To Supply Rese-Cel Using Cellares' Automated Cell Shuttle To Enable Flexible Low-Cost Commercial Scaling

Cabaletta Bio Announces Commercial Agreement With Cellares To Supply Rese-Cel Using Cellares' Automated Cell Shuttle To Enable Flexible Low-Cost Commercial Scaling

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

Cabaletta Bio Reveals Multiple Upcoming Presentations, Including Data on Rese-Cel without Preconditioning and Rese-Cel with Automated Manufacturing, At The ASGCT 2026 Annual Meeting

First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

Cabaletta Bio Doses First Two Patients Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform

This Biotech Stock Could Deliver 350% Returns in 12 Months